Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Invasive Lobular Breast Carcinoma: full-pipeline trial registry
1 of 3 indexed Invasive Lobular Breast Carcinoma trials are currently recruiting.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 1 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Invasive Lobular Breast Carcinoma: 3 US clinical trials tracked, 1 recruiting.
Invasive Lobular Breast Carcinoma is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Alliance for Clinical Trials in Oncology, running 1 of these trials.
Enrollment posture brief
Registry condition invasive-lobular-breast-carcinoma
OPEN 1 | RECR 33% | LATE 1 | EARLY 1 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Invasive Lobular Breast Carcinoma lists 1 open slots (33% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Invasive Lobular Breast Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Invasive Lobular Breast Carcinoma is recruiting below its size-band peers.
1 of 3 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
Blue Earth Diagnostics
NCT07432633
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
Alliance for Clinical Trials in Oncology
NCT01953588
Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer
University of Chicago
NCT01706432
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Invasive Lobular Breast Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Invasive Lobular Breast Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Invasive Lobular Breast Carcinoma page
3 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Invasive Lobular Breast Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Alliance for Clinical Trials in Oncology sponsors the most Invasive Lobular Breast Carcinoma trials on record, review their full trial history before evaluating a specific study. See Alliance for Clinical Trials in Oncology's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Invasive Lobular Breast Carcinoma condition card totals 3 registered trials; most-linked intervention hyperfractionated radiation therapy; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.